Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) EBITDA Margin (2016 - 2025)

Avalo Therapeutics filings provide 10 years of EBITDA Margin readings, the most recent being 23208.47% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 480275.0% to 23208.47% in Q4 2025 year-over-year; TTM through Dec 2025 was 15638.2%, a 767244.0% decrease, with the full-year FY2025 number at 132527.12%, down 12456136.0% from a year prior.
  • EBITDA Margin hit 23208.47% in Q4 2025 for Avalo Therapeutics, down from 18405.73% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 9251.81% in Q3 2024 to a low of 23208.47% in Q4 2025.
  • Median EBITDA Margin over the past 5 years was 1341.16% (2023), compared with a mean of 3986.02%.
  • The widest YoY moves for EBITDA Margin: up 1146706bps in 2024, down -1706457bps in 2024.
  • Avalo Therapeutics' EBITDA Margin stood at 8202.28% in 2021, then surged by 88bps to 988.28% in 2022, then plummeted by -36bps to 1341.16% in 2023, then tumbled by -1272bps to 18405.73% in 2024, then fell by -26bps to 23208.47% in 2025.
  • The last three reported values for EBITDA Margin were 23208.47% (Q4 2025), 18405.73% (Q4 2024), and 9251.81% (Q3 2024) per Business Quant data.